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Innovation is constantly evoked as an imperative to drive growth, however identifying an
actionable and agreed upon deﬁnition that applies to different settings and purposes is not
trivial. In healthcare, innovation has often been described in relation to pharmaceuticals.
Deﬁning innovation allows for proper recognition and rewarding, thus fostering present and
future innovativeness in the system. Current deﬁnitions adopted by payers are focused on
therapeutic added value and more speciﬁcally include clinically signiﬁcant beneﬁt, large health
gains, and favorable risk-beneﬁt balance at an acceptable cost. However, they may not be fully
adequate to assess medical devices. Based on a systematic review of the academic literature in
the ﬁeld, we aim at summarizing acceptable deﬁnitions of innovation in relation to medical
devices. Based on the innovation management and economics theory, proposed deﬁnitions have
been classiﬁed according to the source of innovation, to the degree of discontinuity introduced
and to the impact associated to the technology. They have also been compared with deﬁnitions
adopted for drugs by main healthcare reimbursement agencies. Decision-making in healthcare
often favors static allocative efﬁciency at the expense of incentives to innovate and obtaining
valuable innovation, that is dynamic allocative efﬁciency. In the long run, this attitude may
artiﬁcially shrink net returns from innovation and rebound on the sustainability of the.10.005
raduate Medicine. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
licenses/by-nc-nd/4.0/).
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O. Ciani et al.48healthcare systems, an undesirable consequence that a farsighted shared notion of innovation
should try to prevent.
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The word "innovation" comes from the Latin noun innŏvātĭo.
In lay language use, it refers to the act or process of
introducing new ideas, devices, or methods or to the new
ideas, devices, or methods themselves [1]. In business,
economics and politics, the term is often evoked as an
imperative to drive growth, [2] especially in times of
ﬁnancial crisis for companies, markets and economic insti-
tutions in general [3]. Although the subject has risen to the
core of the debate in many disciplines, including economics
and management theory, and their subﬁeld known as
innovation studies, [4–6] identifying an actionable and
agreed upon deﬁnition that applies to different settings
and purposes is not trivial.
In healthcare, the need to deﬁne innovation in relation to
health technologies comes with the assumption that recog-
nizing and appropriately rewarding innovation will foster
present and future innovativeness in the system [7]. In many
jurisdictions, health policy initiatives are discussed or in
place where innovation is a critical element, often
described in relation to pharmaceutical products [8–11].
New target or novel pharmacological mechanism, method of
synthesis, pharmacokinetic, pharmacodynamic, pharmaco-
genetic or therapeutic features are properties of medicinal
products that can lead to their innovative status [12].
However, the International Society of Drug Bulletins has
explicitly distinguished between innovation that produces
therapeutic advance, in terms of efﬁcacy, safety, and
convenience to patients, and innovation from a purely
commercial (e.g. new molecules that do not produce any
added value) and technological (e.g. biotech products vs
chemical products) viewpoints [13]. More speciﬁcally, the
Italian Society of Hospital Pharmacists has agreed on three
criteria to recognize therapeutic advance. They areevidence from an intervention successful in at least one
randomised superiority trial where the control group is
treated according to the current best practice and the
primary endpoint is clinically relevant [14]. Aronson and
colleagues propose an intentional deﬁnition for innovation
in drug therapy that includes more selective parameters,
i.e. clinically signiﬁcant beneﬁt, large health gains, favor-
able risk-beneﬁt balance at an acceptable cost [7].
However, health technologies are not to be intended as drugs
only. Medical devices have an estimated market of roughly €100
billion in Europe only, and account for about 7.5% of the
healthcare expenditure in most publicly funded healthcare
systems [15]. Besides the extreme diversity and heterogeneity
of products falling under this classiﬁcation, medical devices are
known to differ from drugs in many respects. For instance, for
many of them, especially the implantable devices, their perfor-
mance and use are heavily dependent upon organizational
settings, training, competence, and experience of the operator.
As long as clinicians and their staff do not reach the plateau of
the learning curve, it is difﬁcult to assess the value of new
devices. There might be cases when the plateau is never
reached. This happens when new devices are quickly replaced
by newer generations. Because of their short life cycle, medical
devices do not often beneﬁt from patenting. Moreover, due to
different regulatory and coverage requirements or unavoidable
facts (e.g. difﬁcult, impossible or unethical blinding in clinical
trials), the evidence on added value at market launch is less
robust than for drugs. The value of devices is also more
challenging to assess because they have often multiple indica-
tions (e.g. CT-scan, MRI) or are embedded into procedures or
services. Devices are often diagnostics and their contribution to
ﬁnal health outcomes depend on how the information provided is
treated by the end-users and on what happens to patients
afterwards, therefore it is not easy to parcel out the contribu-
tions of each single components to ﬁnal outcomes [16–18].
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products may not be fully adequate to assess medical
devices, as the properties that drive innovativeness are
different, and scales and thresholds set to capture the
additional beneﬁt of innovative molecules may not be
representative of the marginal beneﬁt produced by other
medical technologies. For instance, if we agreed that
therapeutic advance is an important dimension to capture
and we used the deﬁnition provided by the Italian Society of
Hospital Pharmacists [14], a very small fraction of hundreds
of medical devices recently introduced in the market would
be considered as innovative since only few of them could
claim to base their clinical evidence on “at least one
randomised superiority trial where the control group is
treated according to the current best practice and the
primary endpoint is clinically relevant”. Take the example
of MitraClip (Abbott Vascular Inc. Menlo Park, CA), an
implantable device launched in 2008 allowing a fully
percutaneous approach for mitral regurgitation in non-
operable and high risk patients whose prognosis is very poor
if left untreated. No randomized controlled trials (RCTs)
looking at the appropriate comparator have been completed
so far, nevertheless in 2015 the total number of implants
worldwide amounts to 17.000 already [19]. Does it mean
that Mitraclip is not innovative till a RCT will tell us so or
does it mean we do not know how much innovative it is in
terms of therapeutic added beneﬁt versus its current best
practice till a RCT will measure the number of life years or
quality-adjusted life years (QALYs) gained by those patients
treated with Mitraclip? Provided it is ethical to randomizeFig. 1 Review selection ppatients with poor prognosis to the current best practice
(i.e. medical therapy) when observational evidence already
exists on the efﬁcacy of Mitraclip, in the example given the
deﬁnition and measurement of innovation overlap.
No matter how much narrow or wide it is, the deﬁnition
of innovation endorsed by regulators or decision-makers will
certainly have wide implications for the patients or end-
users, the industry, the citizens and the policy-makers. For
instance, analyzing how innovation in healthcare is deﬁned
might help to lay bare the spill over effects on different
stakeholders as well as for the entire system of care and
beyond, and eventually provide guidance to decision-
makers especially in this period when the new regulation
of medical devices is under discussion at the EU [20].
Therefore, in this study we systematically search for
deﬁnitions of innovation in relation to medical devices as
emerging by the academic literature on the subject and
classify them according to the major classiﬁcations pro-
posed by the innovation management theory. The analysis
aims at enlarging the viewpoint on innovation in medical
technologies, providing healthcare policy-makers with use-
ful insights in the implications of this broaden view such as
fostering the diffusion of worthwhile innovation.Methods
We performed a systematic review of the scientiﬁc peer
reviewed literature discussing the concept of innovation in
relation to medical technologies. This is a commonrocess – ﬂow diagram.
O. Ciani et al.50methodology in public health and comparative effectiveness
research that seeks to systematically and explicitly identify,
select, and appraise studies relevant to a particular
research question, and to collect and analyse data from
the studies that are included in the review [21]. As our topic
is broad and of interest across different disciplines, we
searched several databases for scholarly work: Medline and
Embase, collecting publications from the biomedical and
clinical ﬁelds; Econlit, mainly indexing economic literature;
BusinessSourceComplete and JStore, as comprehensive
databases for policy, management and social sciences aca-
demic journals. We searched for articles that used both
“innovation” and “medical devices” in their titles or
abstracts (see Supplementary Material for search strategies)
from the coverage start of each database up until April
2013. This search yielded 789 titles and abstracts that we
downloaded on a citation manager library. After electronic
deduplication, 597 entries remained for further investiga-
tion (Fig. 1). As we intentionally used a wide search ﬁlter,
we introduced also articles where authors incidentally
adopted both expressions without speciﬁcally providing a
deﬁnition, rather relying on an alleged shared concept of
“innovation”. We therefore checked the abstracts to
exclude those papers where “innovation” was not a major
focus. In order to reduce subjective judgment to a mini-
mum, two reviewers independently performed the screen-
ing on the abstracts, with involvement of a third reviewer
and check of the full-text publication in case of disagree-
ment. This screening resulted in a short list of 90 papers for
full-text examination. Information about included publica-
tions was recorded according to a predeﬁned template and
stored in a local database. We collected data on general
characteristics of the study and deﬁnitions and measures of
innovation proposed by the authors. Systematic reviews
usually include a quality appraisal step. However, quality
checklists developed so far (e.g. Cochrane risk of bias
assessment tool [22]) apply to situations where clinical
studies (e.g. RCTs, observational studies) are assessed in
order to evaluate health interventions. Our study aims are
different hence we decided to present main study char-
acteristics (i.e. journal, design, perspective, technologies
under investigation) without building a de novo quality
appraisal tool that would suit the aim of this study. We
qualitatively analysed the papers to identify how they
deﬁne innovation for medical technologies, either concep-
tually or – by means of speciﬁc measures – empirically. We
then classiﬁed through thematic analysis [23] each of these
applied deﬁnitions according to a framework previously
identiﬁed from the innovation management and economics
theory (see next paragraph). Finally, we contrast the
applied deﬁnitions against current systems in place to value
drug innovation, identify those aspects of innovation that
are speciﬁc to medical devices and discuss implications for
the purpose of the policy-making in healthcare.Theoretical framework for analysis of retained
studies
In order to structure the analysis of deﬁnitions of innovation
in medical devices emerging from the systematic review, we
relied on a framework previously proposed and generallyaccepted in the innovation management and economics
community [24]. This framework includes three classiﬁca-
tions that are brieﬂy introduced below.
Following the innovation management and economics
theory, the retained studies from our systematic review,
or the deﬁnitions of innovation provided by them, can be
classiﬁed according to three broad dimensions: (i) the
source of innovation, (ii) the degree of discontinuity
introduced and (iii) the impact or consequences of
innovation.
According to the ﬁrst dimension, the source of innovation
can be either an emerging need or problem (demand
perspective) or the output of a knowledge-based process
(supply perspective). Problemistic search [25] is the typical
trigger of a demand-pull innovation process that sees
innovation as the result of a searching activity aimed at
coupling speciﬁc problems to solutions, i.e. innovation
happens because individuals face problems and look for
solutions. For example, we could see research on artiﬁcial
pancreas as originating from the need to overcome long-
term consequences in the diabetic population. The supply or
technology-push perspective instead, [26] emphasizes the
entrepreneurial aspects of the innovation process. A popu-
lar example of technology-push innovation is the touch
screen technology. When it ﬁrst appeared in the 1960s,
there was not a precise call from its use. However, its
potential started attracting investments from ﬁrms that
further developed its applications and functions. Of course,
both perspectives can be integrated into a single paradigm-
trajectories framework [27]. Under this unifying framework,
paradigm shifts and trajectories, i.e. developments within
the same paradigm that advance innovation in a problem-
solving perspective, coexist. Hence, technology-push and
demand-pull innovation are not exclusive deﬁnitions, how-
ever the prevalent adoption of either one or the other has
different implications in supervising the user-producer
relationship. In healthcare demand and supply do not
interact independently from the regulatory environment.
This is particularly true in systems where public adminis-
tration plays a major role by deﬁning the amount of
resources available to the healthcare system, translating
needs into demand and structuring decisional systems for
value-based allocation of scarce resources.
The degree of discontinuity, introduced vis-à-vis previous
practice, is the second recurrent trait of technology innova-
tion. According to this dimension, innovations are often
considered as incremental or breakthrough [28,29]. Techno-
logical breakthroughs, or radical innovations, are viewed as a
broad, arching process of scientiﬁc discovery and paradigm
shifts, [27,30] often characterized by an era of ferment and
following convergence into a dominant design or “standard”
[31]. From a dynamic point of view, radical innovations
usually create and deﬁne demands, thus triggering the
development of a set of incremental innovations that may
serve diverse nuances of the newly created needs [32].
Finally, innovation can be deﬁned based on the type,
degree and measure of its impact. Although one may argue
on what constitute real impact, this approach seems
suitable for public health authorities when assessing med-
ical technologies as they are usually expected to be
associated with measurable changes in terms of patients’
beneﬁts, quality of the service or costs.
Table 1 Main characteristics of included studies.
ID First author Journal Year Perspective Type of study Particular MDs subgroup considered in the
study
Other technologies/
industry
1 Traijtenberg Journal of Political Economy 1989 Patient Quantitative Computed tomography scanners None
2 Littell Health Affairs 1994 Industry Quantitative None None
3 Anderson Health Affairs 1994 Industry Commentary None Colony-stimulating fac-
tors, erythropoietin
4 Citron Journal of Biomedical Materi-
als Research
1996 Industry / user Commentary None Vaccines
5 Gullikson Plant, technology and safety
management Series
1996 User Qualitative None None
6 Iserson Seminars in Laparascopic
Surgery
2002 User Commentary Minimally invasive surgery applied to lapara-
scopic cholycistectomy
None
7 Roberts National Academy of Engi-
neering-Institute of Medicine
Symposium
2003 Industry Commentary None None
8 Morscher Scandinavian Journal of
Surgery
2003 User / industry Commentary Total hip replacement None
9 Lexa Journal of American College
of Radiology
2004 Industry Qualitative Radiological technologies None
10 Boyle Expert Review of Medical
Devices
2005 Industry Commentary None None
11 Reitsma Journal of the American Col-
lege of Surgeons
2005 User Quantitative None None
12 Djellal Research Policy 2005 User Qualitative None None
13 Lettl Journal of Engineering &
Technology Management
2007 User/industry Qualitative None None
14 Ghodeswar Journal of Services Research 2007 National Health
System
Qualitative Electromyography None
15 Lettl IEEE Transactions On Engi-
neering Management
2008 User/industry Qualitative Medical robot system, computer-assisted naviga-
tion system for neurosurgery, computer-assisted
navigation system for orthopedics, and radically
new biocompatible implant
None
16 Editorial review (no
authors listed)
Health Affairs 2008 Patient Commentary None None
17 Chatterji Health Affairs 2008 Industry Quantitative None None
18 Graham Berkeley Technology Journal 2009 Industry Quantitative None IT-software and harware,
biotechnologies
19 Karim Management Science 2009 Industry Quantitative None None
20 Consoli Journal of Evolutionary
Economics
2009 Industry Qualitative Coronary artery disease and glaucoma None
21 Lambooij 2010 National Health
System
Quantitative Computed tomography scanners, MRI,
lithotripters
None 51
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Table 1 (continued )
ID First author Journal Year Perspective Type of study Particular MDs subgroup considered in the
study
Other technologies/
industry
International Journal of Tech-
nology Assessment in Health
Care
22 Galbrun Systems Research & Beha-
vioral Science
2010 User Quantitative Computed tomography None
23 Ahn Journal of Commercial
Biotechnology
2010 Industry Qualitative Wound healing sector PC and the digital
industries
24 Weigel European Planning Studies 2011 Industry Qualitative Surgery, orthopaedics and medical imaging None
25 Atluri Expert Review of Medical
Devices
2011 User Qualitative Robotic surgery, valve repair None
26 Moosmayer International Journal of Busi-
ness Research
2011 Industry Quantitative None None
27 Suter New England Journal of
Medicine
2011 Industry Quantitative Knee implant None
28 Morlacchi Research Policy 2011 Industry Qualitative Left Ventricular Assist Device None
29 Davey Irish Journal of Management 2011 Industry Qualitative Stenting for vascular disease, engineered
bladder
None
30 Chandra National Bureau of economic
research bulletin on Aging
and Health
2011 User Qualitative None None
31 Xu Circulation 2012 Industry Qualitative Coronary artery stents None
32 Pullen Creativity and Innovation
Management
2012 Industry Quantitative None None
33 Chatterji Organization Science 2012 Industry Quantitative None None
34 Gosset IEEE Pulse 2012 Industry Commentary None None
35 Smith Medical Care 2013 Industry Qualitative None None
O
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In our systematic review, we identiﬁed 35 publications (see
Supplementary Material) reporting a deﬁnition of innovation
applied to medical technologies out of 90 full-text papers
screened (Fig. 1). The main characteristics of the included
studies are presented in Table 1. They were empirical
studies, with either qualitative (15 out of 35, 43%) [33–47]
or quantitative design (12 out of 35, 34%) [48–59], or
commentary or opinion pieces from experts (8 out of 35,
23%) [60–67]. The vast majority of these studies adopted the
perspective of the industry (20 out of 35, 57%), nine (26%)
reﬂected the view of the users, either patients or profes-
sionals, [34,35,38,40,49,56,58,62,67] and two (6%)
reﬂected the view of the National Healthcare System,
[39,52] with the remainder (11%) taking a combination of
those [41,42,61,64]. The industry perspective focuses on
the innovation-related activities occurring within the ﬁrms
such as inventing new products, processes, or services;
conducting initial research and development; creating
internal tools or processes to build or implement ﬁnal
products, processes, or services; and undertaking the risks
and costs of making, selling, and marketing a commercial
product [50]. User perspectives consider the role of users,
usually clinicians or patients, in generating radically new
ideas and concepts due to their speciﬁc need and problem-
related context [41]; whereas the system perspective is
broader and reﬂects on the general level of innovativeness
within healthcare services or the whole country [52]. All
papers referred to medical devices, however particular
technologies used as good cases of innovation in healthcare
were imaging and radiological technologies, [43,49,52,58]
orthopedic prostheses, [57,64] robotic systems for
computer-assisted surgery, [34,41] left-ventricular assistive
devices [44] and stents for cardiovascular disease
[36,37,47]. The discussion was often extended to innovation
in different industries, such as the biotech pharmaceutical
industry, [60,61] within the medical sector, or the IT and
software industry, [33,50] beyond the healthcare ﬁeld.
Applied deﬁnitions of medical technologies
innovation
Deﬁnitions of innovation reported by study authors are
tabulated in Table 2. They are analysed according to the
three categories derived form the innovation management
and economic theory introduced before.
Deﬁnitions based on the source and boundary
conditions of the innovative process
Building on the supply-driven perspective, [26] several
authors view innovation as an entrepreneurial process
entailing the series of steps taken from the idea to invention
to development to commercialization [50,54,68]. Innova-
tion in medical technologies has been described as the
result of progress along three different pathways: advances
in scientiﬁc understanding, improvement in the ability to
develop new tools and learning in practice [44]. For
instance, with implantable devices for advanced heart
failure (i.e. left ventricular assistive devices) an essentialaspect of the evolution is collective and cumulative learning
or experience gained through the actual use of the technol-
ogy. In such entrepreneurial perspective, the source of
knowledge is not necessarily creative but innovation is also
adoption, that is taking something that someone else had
previously done and applying it in a different milieu [63].
Gelijns and Rosenberg [69] have described the path-
dependent character and cross-disciplinary origin of medi-
cal device innovation [69]. In relation to the interdisciplin-
ary aspect of medical innovation, different authors see
medical innovation as an emergent, nondeterministic pro-
cess generated from complex interactions across hetero-
geneous knowledge bases [49,53]. This links with the
concept of “health innovation systems”, valid for instance
in cardiology and ophthalmology, based on the coexistence
of institutionally-bound interactions among agents, so
called “gateways of innovation” and “pathways of innova-
tion” [36]. Similarly, medical innovations can be seen as
complex bundles of new medical technologies and clinical
services emerging from a highly distributed competence
base [37]. In describing the success of hip replacement
procedure, Morscher states that progress has been achieved
in part through new implant materials and designs that
provided improvements under the biomechanical proﬁle.
However, of at least equal importance, were advances in
operative procedures and in clinical quality control (e.g.
more complete documentation of implant and patient
variables, establishment of implant registers) [64].
From a demand-pull perspective, innovation is a way to
meet speciﬁc needs that ﬁrms or research have ignored or
not yet ﬁgured out to address [48]. Scientiﬁc research is
not the starting point of the innovation circle but, instead,
it appears more like a necessary approach for dealing with
solutions that fall outside the set of solutions suggested by
current knowledge or practice. In this respect, the role of
academia is functional to the interpretation of needs more
than it is to the free search for solutions, as it identiﬁes
the clinical need for certain surgical instruments and
diagnostic services and provide valuable scientiﬁc and
clinical expertise during the early and later stages of
development [60]. Problem-solving may be generated by
the adaptation of existing elements that are modiﬁed,
upgraded and improved to ﬁt new conditions or a change in
the needs [63]. Needs are perceived and expressed by
users, who have been identiﬁed as a crucial factor not only
for the uptake but also for the development of innovations,
often contributing to the deﬁnition of a standard [70,71].
Users becoming entrepreneurs is a particularly common
phenomenon in medicine, for instance surgeons often
develop a new device in response to an issue experienced
in practice and start a company to commercialize it
[72,73]. Although in most areas of medicine what has been
learned is much better characterized as the accumulation
of relative small and local advances than as dramatic
breakthroughs in understanding, [44,47] solutions are
often found far from the status quo or from the existing
set of answers. Unintended consequences of solutions may
derive from uncertainty, unclear preferences and ﬂuid
participation to decisional processes, e.g. adoption deci-
sions in a hospital setting [56]. If these three conditions
occur together, then solutions and problems are coupled
through a “garbage can” approach whereby consequences
Table 2 Deﬁnition of innovation for medical technologies provided by the authors of included studies.
Classiﬁcation First author Year Deﬁnition 1 Deﬁnition 2 Deﬁnition 3
A Littell 1994 Several indicators of inputs and outputs asso-
ciated with medical device innovation,
including public- and private-sector research
and development (R&D) investment, patent
activity, product regulatory clearance pat-
terns, and market acceptance trends.
It is a dynamic, continuous, and interactive
process, rarely proceeding in a linear or
predictable manner. Medical device innova-
tion is characterized more often by small,
incremental steps than by bold, technologi-
cal bounds. The direction of the process is
sensitive to a variety of forces, including the
availability of funds, the reactions of users
and regulators, and more general market
trends.
A Anderson 1994 AHC faculties also have a major impact on
the content of research and development
programs in both the public and private
sectors. They identify the clinical need for
certain drugs, surgical instruments, and diag-
nostic services and provide valuable scientiﬁc
and clinical expertise during their early and
later stages of development.
A Roberts 2003 Radical innovations that introduce dramatic
new capabilities occur, as well as incremental
innovations in those products and processes
that have previously existed. Invention that
is wholly original indeed takes place.
But innovation also includes the adaptation
of things that had come before but are now
being modiﬁed, upgraded and improved to ﬁt
new conditions. Innovation is also adoption,
taking something that someone else had
previously done and applying it in a different
milieu. Another way of distinguishing among
innovations is that some are based upon
science or research, where new knowledge
gets applied, whereas others are clear cases
of engineering problem-solving, applying pri-
marily existing knowledge or techniques to
newly deﬁned problems.
Yet my personal experience,.[..], indicates
that the medical device ﬁeld contradicts all
of the images I have just described. As my
evidence will show, innovation in medical
devices is by and large engineering-based
problem-solving by primarily individuals or
small ﬁrms, that is usually incremental in
character, that seldom reﬂects long periods
of basic research, and that does not in
general depend upon recent generation of
fundamental new knowledge.
A Morscher 2003 For an orthopaedic surgeon research is, ﬁrst
of all, aimed at solving clinical problems.
For industry, on the other hand, research and
development must follow the so-called “S-
curves of development” and continuously and
systematically be directed towards offering
new products that will improve sales. Before
the sales of a current product slow down, the
next product of the same type must already
be “in the pipeline”. Industrial innovation is
also directed at reducing manufacturing
costs, in order to improve proﬁtability.
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Therefore, industrial innovation is aimed
principally at the economic success and
survival of companies. One consequence of
these differences in goals is that today’s
innovation may well be tomorrow’s revision
A Reitsma 2005 Innovation that falls under acceptable every-
day routine variation […] are done on as as-
needed basis and might arise during a proce-
dure or may be planned head for for the
beneﬁt of an individual patient.
Yet when otucomes of procedure are largely
unpredictable because they have not been
previously described, innovation becomes
essentialy experimental and should be con-
ducted, at some point, as a research project.
Differentiating between three categories of
innovation (routine variation, innovation that
is not formal research but requires formal
review, research requireing IRB review)[…]
Forms of surgical innovation fall under the
existing deﬁnition of human subject research
and should be treated as such. For those who
fall short of meeting this deﬁnition [… such
criteria are]: if an innovation is (yet) no part
of a part of a formal investigation, if it is
premeditated because the surgeon seeks to
test a hunch or hypothesis, or theory; if it
differs notably from the existing standard of
care if the outcomes of the proceddure are
not predictable […]; and if it entails serious
risks for complications.
A Graham 2009 "innovation" in its Schumpeterian meaning—
the series of steps taken from idea to inven-
tion to development to commercialization.
Four innovation-related activities:
(a) inventing new products, processes, or
services; (b) conducting initial research and
development; (c) creating internal tools or
processes to build or implement ﬁnal pro-
ducts, processes, or services; and
(d) undertaking the risks and costs of making,
selling, and marketing a commercial product.
As is the case with many innovations in
medical devices, Jeremy was a "user-innova-
tor," seeing a practical problem in his medical
practice that needed a practical response. He
founded his company to offer a product to
meet that need, and quickly secured a patent
A Consoli 2009 The notion of medical innovation is as an
emergent, nondeterministic process gener-
ated from complex interactions across het-
erogeneous knowledge bases.
Medical innovation thus understood [history
of medicine] involves a variety of forms of
knowledge whose evolutionary paths are
rooted in the contexts in which they emerge
and interact.
Medical innovation is an interactive process
involving a broad set of disciplines, agencies
and institutions with close relations emerging
between ﬁrms, clinicians and academic
scientists. More precisely, the process of
division of labor — which in Hayekian terms
can be conﬁgured as the dynamic division of
knowledge in the economy—is distributed
across technological ﬁelds, geographical
domains and organizational units.
A Lambooij 2010 Innovation measured in terms of technology's
output improvement.
A Galbrun 2010 Technological breakthroughs may be generally
viewed as a broad, arching process of scien-
tiﬁc discovery and paradigm shifts, often
characterized by convergence into a standard. 55
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Table 2 (continued )
Classiﬁcation First author Year Deﬁnition 1 Deﬁnition 2 Deﬁnition 3
A Moosmayer 2011 Innovations can be described as serving exist-
ing or creating new market needs.
Radical innovations usually create a need and
thus trigger a set of incremental innovations
that may serve diverse nuances of the newly
created need.
[…] the high importance of uncertainty as a
prerequisite for radical innovations to
become successful, which can be equally
understood as risk and opportunity.
A Morlacchi 2011 […] medical practice evolves as a result of
progress along three different pathways […]
advance in scientiﬁc understanding.[..] the
improvement in the ability to develop new
medical technologies. And learning in prac-
tice has been an extremely important feature
of many medical advances.
In most areas [..] of medicine, what has been
learned is much better characterized as the
accumulation of relative small and local
advances than as dramatic breakthroughs in
understanding. […] The design and develop-
ment of new medical technologies, including
the LVAD which is the focus of this paper,
often has been stimulated and enabled by
the advance of broad technologies whose
principal uses and support lie outside the
realm of medicine.
A Davey 2011 Health innovation consists of complex bun-
dles of new medical technologies and clinical
services emerging from a highly distributed
competence base.
Health innovation systems are driven by the
combination of institutionally bound interac-
tions or ‘gateways’ of innovation and history-
dependent trajectories of change often
referred to as ‘pathways’ of innovation.
A Pullen 2012 In the ﬁeld of high technology innovation is
invention plus commercialization.
[Innovation measured as] 1. The performance
that is achieved as a result of new product
development is the innovation performance,
2. According to Booz et al. (1982) product
innovativeness is the level of newness of the
product to the market and the ﬁrm. In
particular: newness to company and newness
to market; new product-line and new-to-
world products. In newness to company and
to market: Improvements/Revision of exist-
ing products; Cost reduction; Addition to
existing product -lines; Repositionings.
A Smith 2013 The FDA deﬁnes class III devices as “those
that support or sustain human life, are of
substantial importance in preventing impair-
ment of human health, or which present a
potential, unreasonable risk of illness or
injury.
B/A Ahn 2010 Rosenberg has highlighted the fundamental
contribution to medical device innovation
made by individuals. Exceptionally gifted
Literature stresses the Importance of user
involvement for innovation. Users are char-
acterised by a need i.e. an unsolved
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individuals regularly triggered progress by
crossing long-prevailing disciplinary
boundaries.
problem, openness to new technologies, free
space for creative thinking and access to
interdisciplinary expertise.
B/A Xu 2012 Innovative medical devices make major con-
tributions to patient welfare. […] Medical
device innovation occurs in both the public
and private sectors and can generate sub-
stantial economic beneﬁts.
Examining patent literature is a viable way of
assessing the origins of transformative
technology.
B/A Chatterji 2012 "[…] I looked at things and just naturally
thought-"Okay, how can I make this better?"-
Dr T. Fogarty, inventor of more than 70
surgical patents".
In the users' perspective, innovation is a way
to meet often personal needs that ﬁrms have
ignored or have not ﬁgure out to address.
[Innovation measured as] 1. Citations from
outside their technology class. 2. Innovation
in the early stages of the product life cycle
where there is signiﬁcant uncertainty over
dominant design.
B Iserson 2002 Innovations in medicine […] fall into two
broad categories: evolutionary and revolu-
tionary. […] Building on known scientiﬁc
theory and learned skills, they pose few
problems to physicians wishing to add them
to their practice. Revolutionary develope-
ments are, in contrast, the "gee-whiz"
breackthrough drugs or devices that change
aspect of medical care. […] Moreover, revo-
lutionary developments typicallly have sig-
niﬁcant learning curves until physicians
become confortable with their use.
B Djellal 2005 Innovation is considered subjectively, with
the element of novelty being apprehended
in relative rather than absolute terms. It is
also considered extensively in order to
encompass both innovations generated
internally and those originating externally,
that is those adopted from outside sources.
[This decision is reﬂected both] in the nature
of the innovations taken into account (orga-
nizational, technological, product and ser-
vice innovations, etc.) and in the degree of
novelty those innovations display (radical
innovations are included, of course, but so
are minor or incremental innovations possibly
resulting from a simple adaptation or
change).
B Lettl 2007 The fact that our sample of innovative sur-
geons encountered the limits of conventional
technologies motivated them to search for
other, more workable solutions.
B Ghodeswar 2007 An innovation is deﬁned as any product, idea
or practice that is viewed as new by an
individual or the adopting unit.
Incremental innovations make a marginal
improvement over existing technology,
semi-radical innovations represent a signiﬁ-
cant improvement over existing technology,
and radical innovations represent a major or
revolutionary technology advance.
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Table 2 (continued )
Classiﬁcation First author Year Deﬁnition 1 Deﬁnition 2 Deﬁnition 3
B Lettl 2008 From lead user theory, we know that lead
users generate radically new ideas and con-
cepts due to their speciﬁc need and problem-
related context.
Appendix provides a Degree of Innovativeness
Tool grounded on dimensions related to the
innovation process's uncertainty. In particu-
lar, there are: 1) Market dimension: 2) Tech-
nological dimension: 3) Organizational
dimension.
B Chatterji 2008 One measure of the importance of a patented
innovation involves counting the number of
citations it receives in subsequent patents.
[…] A second way to measure the impact of a
patented invention is to consider the breadth
of technological space that it inﬂuences.
Patents that inﬂuence follow-on technologies
across a more diverse set of areas have a
broader impact. BronwynHall and colleagues
found that one additional citation increased
the ﬁrm’s market value by more than
3 percent.
B Weigel 2011 Innovation measured in terms of clinical
indicators of improvement.
B/C Traijtenberg 1989 Product innovation can be thought of in terms
of changes over time in the set of available
products, in the sense that new brands
apprear and that there improvements in the
qualities of exiting products.
C Citron 1996 The impact has been most pronounced for
those technologies that could mature to
become technological breakthroughs, the
major advancements in therapy.
C Gullikson 1996 Technology assessment is an essential tool for
new medical technologies management that
allows to control negative legal and economic
consequences by assessing risk throughout
the medical equipment lifecycle. The risk
level assigned to each technology depends
on a number of static or dynamic risk factors
(e.g. maintenance requirement, equipment
function).
C Lexa 2004 In our ﬁeld a dramatic example is the end of
pneumoencephelography with the introduc-
tion of computed tomography scanner, This a
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striking example of reltively rapid replace-
ment. […] Schumpeter termed this latter
phenomena "creative destruction", and it is
part and parcel of the most successful and
signiﬁcant effort of entrepereneur. Some-
times that destruction does not occur if two
technologies are fairly robust.
C Boyle 2005 […] research impact can be measured with
the rate of citations by other researcher
obtained by bibliometric database or com-
mercialization outputs was developed by
collecting the relative citation impact data
for eight health and medical reserach ﬁelds
in a group of developed countries, number of
patents, number of licenses executed,
amount of gross income from licenses, num-
ber of start-up companies.
C Editorial
review
2008 […] unless the innovation is not what it's
cracked up to be and does not really produce
better care or outcomes.
C Karim 2009 Innovation is generally considered to be the
creation of new resources by the ﬁrm. In this
paper, innovation is observed at the product
level and is radical, representing internal
entry (i.e., not via acquisition) into new
product markets. Incremental innovations,
namely changes within existing product lines.
Innovation literature has addressed how new
resource combinations or similar resources
combined in new ways (i.e., recombination)
may result in innovation. […] Stemming from
Schumpeter’s concept of creative destruction,
architectural innovation refers to new links
between components within product architec-
tures. Other scholars have theorized about
the characteristics of knowledge affecting
resource recombination and innovation, as
well as knowledge itself (comprised of infor-
mation and know-how) being a recombined
resource that leads to market opportunities.
C Atluri 2011 Decreased pain, more rapid return to work,
reduced blood loss and length of hospitaliza-
tion have been associated with technological
advances leading to minimally invasive sur-
gery. The improvements in visualization and
rotational freedom may be difﬁcult to justify
in face of the added cost.
C Suter 2011 Medical device innovation continues […]
Most are designed to improve durability, and
their manufacturers cite laboratory studies
showing reductions in wear.
Innovations are typically accompanied by
cost increases, and devices providing small,
incremental clinical beneﬁts may be less
likely to offer good value for any additional
investment. 59
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O. Ciani et al.60of new elements are often beyond the control of involved
actors [74].
In terms of regulation of healthcare markets, commonly
justiﬁed on the basis of well-known market failures, [75]
Lambooij et al. [52] found evidence that decisions by
healthcare professionals on which innovation to adopt is
embedded in a context that is inﬂuenced and shaped by the
availability of resources on macro level and concluded that
setting the level of resources available, as well as deﬁning
the rules of the game, deeply affects the choices of both
physicians and companies. Smith and Sfekas [45] discuss
instead the negative consequences of imposing ﬁnancial
restrictions on the producer-user relationship, generally
applied to reduce the conﬂict of interest based on informa-
tion asymmetries between physicians and decision-makers.Deﬁnitions based on the degree of discontinuity
Based on the level of discontinuity observed, innovation can
be classiﬁed as radical or incremental [28]. More speciﬁ-
cally, Iserson and Chiasson [62] note that innovation in
medicine falls into two broad categories: evolutionary and
revolutionary. Building on known scientiﬁc theory and
learned skills, evolutionary innovations pose few problems
to physicians wishing to add them to their practice.
Revolutionary developments are, in contrast, the "gee-
whiz" breakthrough devices that change aspect of medical
care. Semi-radical innovations represent a signiﬁcant
rather than a major improvement over existing technology
[39]. In order to operationalize the measure of degree of
discontinuity, patent citations’ counts have been adopted.
The advantage of patent citations’ counts is that they allow
both the identiﬁcation of the pieces of knowledge that have
been integrated in a new entity and, over time, the spaces
of knowledge that the new entity has contributed to
generate. For example, Chatterji et al. [59] used patent
data to evaluate the cooperation between industry and
physicians in medical innovative processes. However, mea-
suring discontinuity using patent counts could play at best
the role of proxy, [58] as they capture a limited amount of
information throughout the innovation process. The sub-
jective nature of the magnitude of innovation is initially
recognized by Rogers and Shoemaker [30] who included
individual perceptions in the deﬁnition of innovation as any
product, idea or practice that is viewed as new by an
individual or the adopting unit. In a similar way, Djellal and
Gallouj [38] describe the concept of innovation in hospitals
as multifaceted, with multiple dimensions falling in the
realm of users’ perceptions. The subjective facet of
discontinuity de-objectiﬁes the measurement of innovation
and introduces the user as an endogenous element of
innovation, instead of reducing its role to a mere compo-
nent of the technology, technological complement or
source of information about needs [70,71]. Users are
characterized by a need, i.e. an unsolved problem, open-
ness to new technologies, free space for creative thinking
and access to interdisciplinary expertise [33,46]. Even
though their role could be understood as limited to some
phases of innovation, many studies have considered their
contribution as a resource to the ﬁrm [42,47,48]. The role
of users is explicitly addressed by Lettl [41,42] whose focus
61De innovatione: The concept of innovation for medical technologies and its implications for healthcare policy-makingis on users as promoters of creative search and inventors
and (co)-developers of radical innovations. By examining
the role of surgeons in developing robotic and computer
assisted navigation systems, he observed that encountering
the limits of conventional technologies motivated them to
search for other, more workable solutions [42].Deﬁnitions based on innovation’s impact and
consequences
When innovation in medical devices is identiﬁed by its
impact on the intended outcome, the underlying deﬁnition
is actually overlapping with its measurement. In fact, some
authors focusing on the impact of innovation leave the
deﬁnition implicit in the proposed measure. The impact on
patient beneﬁt is a common reference measure of innova-
tion, often associated with costs [57,66]. As Trajtenberg
states, [58] the necessary condition for a technical advance
to be innovative was to generate additional consumer
surplus in that ﬁeld and time. What is a consumer surplus
is rooted in microeconomic theory, [76] as Trajtenberg
clearly states that the appropriate measure of surplus is
welfare, as the "magnitude" of innovations equates the
welfare gains they generate [58]. Cost-effectiveness is a
convenient measure to simultaneously look at health out-
comes and costs, and categories of innovation based on
average cost-effectiveness have also been proposed [35].
Gullikson et al. suggest technology assessment as a tool for
innovative medical technologies management that allows to
control negative legal and economic consequences by
assessing risk throughout the medical equipment lifecycle
[40]. In 1996, Citron [61] suggested to measure innovations
on the extent to which they meet and satisfy patients’
needs, as some forms of clinical or patient-relevant indi-
cator should be an essential component of innovation
measurement [34]. Measuring impacts on relevant out-
comes, such as better care, has been proposed as a
necessary condition for rewarding innovators [67]. Under a
service-delivery perspective, Boyle et al. [65] deﬁned
innovation as the ability of a new element to produce a
variation in either the quality of healthcare or its costs. In
this sense, the impact of innovation can fall outside the
speciﬁc beneﬁt to patients and users. Generally speaking,
an innovation has usually an impact on interdependent
technological systems, as well as on the society and social
actors that are directly or indirectly inﬂuenced by the
continuous need of advancing science and technology. The
concept of “creative destruction”, imported by Schumpeter
from Marxist theory of capitalism, [77,78] can describe how
the need for continuous advancement in scientiﬁc knowl-
edge and technological progress negatively impact on the
stability of pre-existing equilibria. Lexa [43] provided an
example of creative destruction when discussing the case of
the introduction of computer tomography scanners, at the
expense of pneumo-encephalography. Other authors
reshaped the concept in an organizational perspective
[51,79]. They highlight that some innovations might have
negative or unintended consequences mediated by the
necessity of exposing ﬁrms to risky changes or by over-
looking complementary element of the technological
endowment of an organization.Discussion
Our literature review shows that innovation in relation to
medical devices has been deﬁned in several ways, each
focusing on speciﬁc traits of this multidimensional concept,
often inﬂuenced by the perspective layer taken.
This broader concept of innovation contrasts with the
narrower viewpoint taken by payers when assessing drugs.
If we look at currently available tools of grading innovation
at major reimbursement agencies around Europe, we see
that they are mainly related to pharmaceuticals and rely
upon the concept of therapeutic added value. In terms of
categorical scales, the Transparency Commission of the
French Health National Authority (HAS) grades the medical
beneﬁt assessment (ASMR) in ﬁve levels of therapeutic
beneﬁt [8]. The additional beneﬁt of pharmaceuticals is
categorised in six levels by the Federal Joint Committee
according to the German Act on the Reform of the Market
for Medical Products (AMNOG) [9]. In Italy the National
Drug Agency (AIFA) has introduced in 2007a scale of
innovativeness based on the availability of therapeutic
alternatives (e.g. no alternatives or absolute contraindica-
tion to patients sub-groups; patients who do not respond
to existing alternatives; presence of alternatives for the
same indication) and added therapeutic value (e.g. major
effects on ﬁnal or surrogate validated endpoints; partial
beneﬁts on surrogate endpoints; minor or temporary
impacts on symptoms) [10]. By fulﬁlling the accepted
deﬁnitions of innovative drug in these countries, the
manufacturers gain speciﬁc advantages: in France the
ASMR is taken into account during price negotiation;
discounts over list prices for drugs covered by the German
Social Health Insurance are partially driven by beneﬁt
assessment [80]; in Italy drugs with a major added value
are allowed to bypass further locally appraisal steps [81].
When comparing the emerging deﬁnitions of innovation
found in the literature for medical devices with the
current systems adopted to value drug innovation by
payers, the main conclusion is that the meanings suggested
by the scientiﬁc literature go beyond the change in the
health outcomes, or therapeutic value, usually adopted by
payers when appraising pharmaceuticals. On top of mea-
sures of clinically meaningful beneﬁt, innovation, cer-
tainly when referred to medical technologies, usually
encompasses a number of additional interrelated dimen-
sions and consequences at the level of user/consumer,
single organizations or whole system that have largely
been overlooked by innovation scales used so far. These
relate to meeting patients’ or users’ preferences, creating
organizational features to improve quality or efﬁciency in
service delivery, or fostering the overall innovativeness of
the system.
In terms of degree of discontinuity introduced by innova-
tion, available frameworks set different thresholds of
uncertain origins that are barely applicable to medical
technologies. Whilst occasionally single breakthrough tech-
nologies produces signiﬁcant health gains in the reference
population, further reﬁnements of the technology itself or
its use have produced important cumulative impact and
better outcomes than would have been achieved by the
initial technology [82]. This is the case with left ventricular
assistive devices [83] or new fenestrated or chimney
O. Ciani et al.62versions of the endovascular repair of aortic aneurysms. In
addition, when considering the degree of innovation, payers
look at it ex post, i.e. in terms of results reached, and often
seek to conﬁrm with real world data what has been found in
clinical experiments. On the other hand, applied deﬁnitions
of breakthrough innovation in the academic literature
envisages an ex ante paradigm shift. Hence, uncertainty is
a major contextual factor in emerging deﬁnitions. It has
been listed as a prerequisite for radical innovations to
become successful, [84] that is an alternative way of
framing the risk and opportunity trade-off [54]. Otherwise,
this is a consequence of the focus payers give to static
allocative efﬁciency or an ever more restricted cost-
containment approach, whereas other policy-makers may
be heralds of a dynamic and systemic vision of innovation,
provided that a breakthrough innovation will activate future
incremental innovations.
Another important aspect emerging from the literature is
the crucial role played by the health innovation system and
relationships among its players. Several authors stressed the
relevance of relationships among organizations and single
individuals, with a particular focus on relationships between
users/clinicians and the industry, and the crucial role played
by target users, particularly lead users. The relationship
between lead users and the industry is considered a crucial
factor for the development of innovations that become a
standard for the future. Therefore, initiatives aimed at
strengthening the relationships between users of medical
devices and the industry should be encouraged. These may
include actions intended to strengthen ideas into products
or technology transfer initiatives, but also informal inter-
action within activities aimed at promoting a new technol-
ogy (e.g. conferences, joint publications) [85]. Sustained
and continuous interaction may enhance unpredicted con-
sequences of the innovation process, ﬂuid participation to
decisional processes is a known factor inﬂuencing the
coupling between problems and solutions. In this respect,
also relationships between the industry and policy-makers,
i.e. regulators and payers, in the forms of early scientiﬁc
advice or public consultation should also be encouraged.
Open innovation systems’ beneﬁts have been described also
in hightech medical device companies as they can more
easily capture the multifaceted ideas of scientists, engi-
neers, clinicians and indeed patients [37].
We acknowledge potential limitations of this study
whilst gauging its ﬁndings. First and foremost, we relied
on published academic publications. Although other
sources, such as policy briefs or magazines, may provide
alternative deﬁnitions of innovation, the body of knowl-
edge developed by the scientiﬁc community through peer-
reviewed publications around the topic may be considered
as an unbiased and expert source for the purpose of our
study. We did not perform a formal quality appraisal of
included papers in this systematic review because of the
aim of this study (i.e. identifying deﬁnitions of innovation
and not evaluating healthcare interventions). Also, we did
not perform a systematic search for current available
scales for innovation. We described and referred to
evaluation frameworks in place at main public healthcare
agencies in Europe, which, to the best of our knowledge,
represent the most advanced attempts for grading innova-
tion in health products.Conclusion
Overall, our review found that innovation for medical
devices has an important multidimensional and perceptive
facet that should not be limited to therapeutic added value
under the healthcare policy-makers perspective.
Policy-makers play an important role in the process of
innovation since they intervene in different phases, and
with multiple consequences, in the market relationships
between innovators, producers, users and patients. The
presence of regulation and policy in healthcare markets is
generally justiﬁed on the basis of the relevance of market
failures. Policy-makers are, therefore, expected to correct
the negative consequences on outcomes, equity and sus-
tainability that a free healthcare market would inevitably
imply. In other words, policy-makers set the boundary
conditions of the market by determining the rules of
interaction between healthcare actors and by selecting
the sample of services and goods that can be made
available. According to the system, they also set payment
and reimbursement conditions. Under a static efﬁciency
perspective, the role of policy-makers is exogenous with
respect to the process innovation. However, with respect to
dynamic efﬁciency, a trade-off may emerge between ensur-
ing a static beneﬁcial equilibrium and giving sufﬁcient
incentives to market actors to constantly improve goods
and services available in healthcare. Whilst ex-ante indus-
trial policies aiming at supporting innovation and research
cover different ﬁelds, direct incentives to sustain health-
care applications may still be useful. The responsibility of
tight constraints and regulation goes, therefore, beyond the
short-term need of ensuring sustainability to the system and
information caveats on therapeutic added value at market
launch. It impacts companies’ ability to innovate by two
mechanisms. First, tight regulation and constraints reduce
the expected returns of innovation, by raising the minimum
expected incremental contribution of a new product or
service. Second, it increases the costs of innovation by
limiting the potential synergies between demand and
supply. In the long run, this situation may rebound on the
sustainability conditions of the healthcare systems as arti-
ﬁcial shrinks of net returns from innovation, an undesirable
consequence that professionals at any level should try to
prevent.Author statements
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